FDA approval of a generic pomalidomide formulation; confirms bioequivalence to reference but does not report clinical efficacy or comparative trial data.
Reported
Approval status date2026-08-31
Loading
Drug or technology
4 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of a generic pomalidomide formulation; confirms bioequivalence to reference but does not report clinical efficacy or comparative trial data.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide; this is a regulatory action, not a clinical evidence assessment.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide generic formulations; this is a regulatory action, not clinical evidence of efficacy or safety.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide; establishes regulatory requirements but does not report clinical efficacy or safety trial outcomes.